Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 1.00 |
| ▸ | LCK | P06239 | 8/20 | 1.00 |
| ▸ | TEK | Q02763 | 7/20 | 1.00 |
| ▸ | KDR | P35968 | 6/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 2/20 | 1.00 |
| ▸ | RAF1 | P04049 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 9/20 | 0.43 |
| ▸ | GAK | O14976 | 3/20 | 0.43 |
| ▸ | FBP1 | P09467 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.40 |
| ▸ | BUB1 | O43683 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2519650 | 0.91 | BRAF (0.84) | BRAFLCKTEKKDRMAPK14 | |
| SCHEMBL11889290 | 0.88 | BRAF (0.79) | BRAFLCKTEKKDRMAPK14 | |
| SCHEMBL2265173 | 0.88 | TEK (0.78) | BRAFLCKTEKKDRMAPK14 | |
| SCHEMBL11889113 | 0.88 | BRAF (0.78) | BRAFLCKTEKKDRMAPK14 | |
| SCHEMBL11888951 | 0.87 | BRAF (0.84) | BRAFLCKTEKKDRMAPK14 | |
| SCHEMBL11889511 | 0.87 | BRAF (0.83) | BRAFLCKTEKKDRMAPK14 | |
| SCHEMBL2520976 | 0.87 | BRAF (0.77) | BRAFLCKTEKKDRMAPK14 | |
| SCHEMBL11889198 | 0.85 | BRAF (0.74) | BRAFLCKTEKKDRMAPK14 | |
| SCHEMBL2517998 | 0.85 | BRAF (0.74) | BRAFLCKTEKKDRMAPK14 | |
| SCHEMBL11889039 | 0.85 | BRAF (0.74) | BRAFLCKTEKKDRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11197861-B2 | Methods of screening BRaf inhibitors for treating cutaneous reactions | LUTRIS PHARMA LTD. (IL) | 2021-12-14 | — | — | US | disclosed |
| US-20210346389-A1 | USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF RADIATION DERMATITIS | LUTRIS PHARMA LTD (IL) | 2021-11-11 | — | — | US | disclosed |
| US-20200147090-A1 | METHODS OF SCREENING BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS | LUTRIS PHARMA LTD (IL) | 2020-05-14 | — | — | US | disclosed |
| US-10632123-B2 | Use of BRaf inhibitors for treating cutaneous reactions | LUTRIS PHARMA LTD. (IL) | 2020-04-28 | — | — | US | disclosed |
| US-20130226549-A1 | STRUCTURE-BASED FRAGMENT HOPPING FOR LEAD OPTIMIZATION AND IMPROVEMENT IN SYNTHETIC ACCESSIBILITY | TSENG, YUFENG J. (TW) | 2013-08-29 | — | — | US | disclosed |
| US-20130226549-A1 | STRUCTURE-BASED FRAGMENT HOPPING FOR LEAD OPTIMIZATION AND IMPROVEMENT IN SYNTHETIC ACCESSIBILITY | TSENG, YUFENG J. (TW) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346389-A1 | USE OF TOPICAL BRAF INHIBITOR COMPOSITIONS FOR TREATMENT OF RADIATION DERMATITIS | BRAF, NRAS, RAF1 | BRAF 1/4885LCK 9/4885TEK 1296/4885 |
| US-10632123-B2 | Use of BRaf inhibitors for treating cutaneous reactions | BRAF, ERBB3, PIK3C3 | BRAF 1/4885LCK 19/4885TEK 377/4885 |
| US-11197861-B2 | Methods of screening BRaf inhibitors for treating cutaneous reactions | BRAF, EGFR, ERBB2 | BRAF 1/4885LCK 19/4885TEK 634/4885 |
| US-20200147090-A1 | METHODS OF SCREENING BRAF INHIBITORS FOR TREATING CUTANEOUS REACTIONS | BRAF, EGFR, ERBB2 | BRAF 1/4885LCK 19/4885TEK 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.